These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33692348)

  • 1. Formal reply to "Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX".
    Feuerbach L
    Nat Commun; 2021 Mar; 12(1):1551. PubMed ID: 33692348
    [No Abstract]   [Full Text] [Related]  

  • 2. Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX.
    de Nonneville A; Reddel RR
    Nat Commun; 2021 Mar; 12(1):1552. PubMed ID: 33692341
    [No Abstract]   [Full Text] [Related]  

  • 3. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
    Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
    Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
    Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
    Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
    Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM
    Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization.
    Li F; Deng Z; Zhang L; Wu C; Jin Y; Hwang I; Vladimirova O; Xu L; Yang L; Lu B; Dheekollu J; Li JY; Feng H; Hu J; Vakoc CR; Ying H; Paik J; Lieberman PM; Zheng H
    EMBO J; 2019 Oct; 38(19):e96659. PubMed ID: 31454099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
    Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
    Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
    de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
    Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity.
    Lovejoy CA; Takai K; Huh MS; Picketts DJ; de Lange T
    PLoS Biol; 2020 Jan; 18(1):e3000594. PubMed ID: 31895940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compromised Telomeric Heterochromatin Promotes ALTernative Lengthening of Telomeres.
    Voon HPJ; Collas P; Wong LH
    Trends Cancer; 2016 Mar; 2(3):114-116. PubMed ID: 28741530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chromatin remodeler complex ATRX-DAXX-H3.3 and telomere length in meningiomas.
    Cavalcante SG; Pereira BJA; Lerario AM; Sola PR; Oba-Shinjo SM; Marie SKN
    Clin Neurol Neurosurg; 2021 Nov; 210():106962. PubMed ID: 34624827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
    Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
    Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered telomeres in tumors with ATRX and DAXX mutations.
    Heaphy CM; de Wilde RF; Jiao Y; Klein AP; Edil BH; Shi C; Bettegowda C; Rodriguez FJ; Eberhart CG; Hebbar S; Offerhaus GJ; McLendon R; Rasheed BA; He Y; Yan H; Bigner DD; Oba-Shinjo SM; Marie SK; Riggins GJ; Kinzler KW; Vogelstein B; Hruban RH; Maitra A; Papadopoulos N; Meeker AK
    Science; 2011 Jul; 333(6041):425. PubMed ID: 21719641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
    Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
    Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATRX/DAXX: Guarding the Genome against the Hazards of ALT.
    Clatterbuck Soper SF; Meltzer PS
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
    Heaphy CM; Singhi AD
    Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
    Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
    Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
    Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
    Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
    Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
    Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.